Skip to content

Listen to The Perfect Scam Podcast and Nominate It for a People’s Choice Podcast Award! Find Out More

 

Hospitals Grapple With a Painkiller Shortage

A dearth of injected opioids forces the use of less effective pills

A doctor preparing an injection or shot

Getty Images

Hospitals are facing a shortage of injected opioid pain medications.

There is another opioid crisis happening in the U.S., and it has nothing to do with the overdose epidemic: Hospitals are frequently running out of widely used injected painkillers.

Manufacturing shortages are forcing many doctors and pharmacists to sometimes ration injected opioids, reserving them for the patients suffering most. Other patients get slower-acting or less effective pain pills, alternatives with more side effects, or even sedation.

Medical groups are urging regulators to help, saying some people having surgery, fighting cancer or suffering with severe burns are getting inadequate pain control. They also say shortages frequently cause medication switches that could lead to deadly mistakes.

The American Medical Association this month declared drug shortages a public health crisis, saying it will urge federal agencies to examine the problem as a national security threat and perhaps designate medicine factories as critical infrastructure.

Injected opioid shortages also happened in 2001 and 2010, but they weren't as acute and long-lived, experts say. This one started almost a year ago and is expected to last into next year.

"It's definitely the most severe I've seen in tracking drug shortages for 17 years," says Erin Fox, a University of Utah Hospitals pharmacist. She tracks national medicine shortages and recalls two patients dying due to medication errors during the 2010 shortage.

Such shortages steal time from patient care, increase hospitals' costs and affect just about every department, including operating rooms, emergency departments and cancer clinics. Doctors occasionally find opioids missing from emergency carts and surgery supply trays, "borrowed" by colleagues needing them for other patients.

The shortages started hitting hospitals last summer, after the Food and Drug Administration found unsterile conditions and other serious problems at a Pfizer factory in Kansas. The company, which makes 60 percent of the country's injected opioids, had to slash production to fix the problems.

By January, shortages were so bad hospitals started creating teams to manage their supplies, said Michael Ganio, director of pharmacy practice at the 45,000-member American Society of Health-System Pharmacists.

The group's April survey of 343 hospital pharmacists found 98 percent had dealt with moderate or severe shortages of the key opioids for treating serious pain: morphine, fentanyl and hydromorphone, better known as Dilaudid. Many hospitals were completely out of at least one.

Shortages of generic injected drugs have become normal. Profit margins are tiny, so only a handful of companies make them, and none can dramatically increase production when a rival stops manufacturing.

With the opioid shortages lingering, hospitals and medical groups have set guidelines for stretching supply, including transferring injected painkillers from large vials into several smaller ones or syringes.

Valerie Jensen, the FDA's head of drug shortages, says the shortages triggered by Pfizer's problems may ease slightly in the next few months.

The three much-smaller makers of injected opioids — Fresenius Kabi, West Ward and Akorn — have begun making more. They're putting factory workers on overtime, adding shifts and switching some manufacturing lines from less-crucial medicines to injected opioids.

The FDA has been expediting approvals those companies need to make more opioids, including allowing new product formulations.

The agency also let Pfizer distribute some glass syringes prefilled with opioids that were held back because of possible particle contamination and cracks in stoppers. Hospital pharmacists have to examine each syringe closely and then filter the contents in a complex, multistep process.

Meanwhile, Pfizer doesn't expect to have most of its injectable opioids back in full supply until the first quarter of 2019, says John Kelly, the firm's head of manufacturing quality.

The New York-based company acquired the McPherson, Kan., factory when it bought the drugmaker Hospira in 2015. To fix the plant's troubles, Pfizer decided to replace production lines and other technology, particularly huge equipment-sterilizing machines called autoclaves that can take two years to build, install and test. It's spent more than $300 million so far.

Planned shutdowns last summer to start upgrades took longer than expected, FDA inspectors found other problems that needed fixing, and product demand rose, triggering shortages, says Kelly. He says production now is increasing somewhat each week.

More on Opioids

Join the Discussion

0 | Add Yours

Please leave your comment below.

You must be logged in to leave a comment.

GO TO THIS ARTICLE